ArticleDiscover oncology2026
The risk and prognosis factors of second primary malignancies in hepatocellular carcinoma survivors.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWith the prolongation of life expectancy in hepatocellular carcinoma (HCC) patients attributed to the advancement of treatments, the morbidity of second primary malignancies (SPM) has attracted considerable academic attention. The study aimed to probe into the risk and prognostic factors of SPM in HCC survivors.
methodsAll information about the participants was extracted from the Surveillance, Epidemiology, and End Results (SEER) database. The competing risk regression and LASSO regression were adopted to establish a nomogram for SPM prediction. The validity of the nomogram was authenticated by concordance index (C-index), calibration curves, and receiver operating characteristic curves (ROC). Cox regression and Kaplan–Meier curves were utilized for survival analysis of SPM patients.
resultsA total of 2491 cases were enrolled in the research, with 182 (7.31%) patients developing SPMs in the follow-up duration. The median follow-up time of second primary malignancy patients (67 months) was longer than that of non-second primary malignancy patients (30 months). The nomogram for the occurrence of SPM was created with age, grade, AJCC, chemotherapy and surgery. Covariates such as age, sex, distant tumor stage, surgery, latency and tumor type, had an impact on OS or CSS of SPM patients respectively based on the outcome of survival analysis.
conclusionOur study identified crucial predictive indicators for the risk of SPM in HCC survivors and the prognosis of SPM patients. The nomogram constructed for estimating the probability of SPM performed well. These findings may provide clinicians with meritorious suggestions on surveillance and management of SPMs in HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.